Esperion Therapeutics Inc (ESPR)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
ESPR
Esperion Therapeutics Inc
$3.18
0.00%
HEALTHCARE · Cap: $819.47M
TAK
Takeda Pharmaceutical Co Ltd ADR
$17.25
-2.82%
HEALTHCARE · Cap: $55.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 1077195% more annual revenue ($4.51T vs $418.24M). ESPR leads profitability with a -1.8% profit margin vs -3.4%. TAK earns a higher WallStSmart Score of 57/100 (C).
ESPR
Avoid34
out of 100
Grade: F
TAK
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 23.2% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -260.8% — below average capital efficiency
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ESPR
The strongest argument for ESPR centers on Debt/Equity, Revenue Growth. Revenue growth of 23.2% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.
Bear Case : ESPR
The primary concerns for ESPR are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
ESPR profiles as a growth stock while TAK is a turnaround play — different risk/reward profiles.
ESPR carries more volatility with a beta of 1.06 — expect wider price swings.
ESPR is growing revenue faster at 23.2% — sustainability is the question.
ESPR generates stronger free cash flow (-28M), providing more financial flexibility.
Bottom Line
TAK scores higher overall (57/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Esperion Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?